Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 22.47M | 21.29M | 20.42M | 18.80M | 17.88M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 94.05M | 82.97M | 76.24M | 68.68M | 68.15M |
Operating Income | -94.05M | -82.97M | -76.24M | -68.68M | -68.15M |
Income Before Tax | -90.92M | -78.78M | -71.27M | -63.53M | -62.44M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -90.92 | -78.78 | -71.27 | -63.53 | -62.44 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -90.92M | -78.78M | -71.27M | -63.53M | -62.44M |
EBIT | -94.05M | -82.97M | -76.24M | -68.68M | -68.15M |
EBITDA | -92.73M | -81.61M | -74.87M | -67.27M | -67.01M |
EPS Basic | -6.02 | -5.25 | -4.87 | -4.75 | -5.10 |
Normalized Basic EPS | -3.76 | -3.28 | -3.04 | -2.97 | -3.21 |
EPS Diluted | -6.02 | -5.25 | -4.87 | -4.75 | -5.10 |
Normalized Diluted EPS | -3.76 | -3.28 | -3.04 | -2.97 | -3.21 |
Average Basic Shares Outstanding | 60.37M | 60.02M | 58.33M | 54.37M | 50.34M |
Average Diluted Shares Outstanding | 60.37M | 60.02M | 58.33M | 54.37M | 50.34M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |